SecBot SecBot
SECBOTREPLAY Home › Report › MYGN

MYGN · Myriad Genetics announced FDA approval of its MyChoice® CDx Test as the…

Myriad Genetics, Inc. · PRESS-RELEASE filed Mar 17, 2026 at 16:05 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 17, 2026 at 16:05 ET

Myriad Genetics announced FDA approval of its MyChoice® CDx Test as the companion diagnostic for GSK's Zejula (niraparib) in advanced ovarian cancer patients, based on the PRIMA trial data. This makes MyChoice CDx the only FDA-approved test in the U.S. to identify HRD-positive patients eligible for Zejula, reinforcing Myriad's leadership in ovarian cancer diagnostics and expanding the commercial utility of its test.

  • FDA approved Myriad's MyChoice® CDx Test as the companion diagnostic for GSK's Zejula in advanced ovarian cancer.
  • The approval is based on final data from the PRIMA trial, using HRD status to stratify patients.
  • MyChoice CDx is now the only FDA-approved HRD test in the U.S. for PARP inhibitor eligibility with Zejula.
  • The test identifies HRD status via comprehensive BRCA1/2 analysis and genomic instability score (GIS).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access